Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models of pain. Herein, we have investigated their relevance in neuropathic pain induced by brachial plexus avulsion (BPA) in mice. day. Treatment with WIN 55,212-2 prevented the activation of both glial cells and MAP kinases, associated with an enhancement of CREB and NF-κB activation.Our results indicate a relevant role for cannabinoid agonists in BPA, reinforcing their potential therapeutic relevance for the management of chronic pain states
Abstract Background Targeting the endocannabinoid system has emerged as an effective strategy for th...
The CB2R agonist AM1710, examined in animal models of peripheral neuropathy, is effective in control...
A great need exists for the development of new medications to treat pain resulting from various dise...
Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models...
Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models...
Neuropathic pain is a devastating neurological disease that seriously affects quality of life in pat...
Spinal glial activation contributes to the development and maintenance of chronic pain states, inclu...
The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We inves...
Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allo...
Cannabinoid CB2 receptor activation by selective agonists has been shown to produce analgesic effect...
Many reports have shown the efficacy of cannabinoid agonists in chronic pain, whereas no report exis...
Neuropathic pain is a clinical manifestation of nerve injury difficult to treat even with potent ana...
An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in ...
Chronic neuropathic pain is often difficult to treat due to its resistance to therapeutic interventi...
Approximately twenty million people in United States have some form of peripheral neuropathy. It has...
Abstract Background Targeting the endocannabinoid system has emerged as an effective strategy for th...
The CB2R agonist AM1710, examined in animal models of peripheral neuropathy, is effective in control...
A great need exists for the development of new medications to treat pain resulting from various dise...
Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models...
Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models...
Neuropathic pain is a devastating neurological disease that seriously affects quality of life in pat...
Spinal glial activation contributes to the development and maintenance of chronic pain states, inclu...
The antinociceptive properties of cannabinoids in persistent pain are not fully elucidated. We inves...
Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allo...
Cannabinoid CB2 receptor activation by selective agonists has been shown to produce analgesic effect...
Many reports have shown the efficacy of cannabinoid agonists in chronic pain, whereas no report exis...
Neuropathic pain is a clinical manifestation of nerve injury difficult to treat even with potent ana...
An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in ...
Chronic neuropathic pain is often difficult to treat due to its resistance to therapeutic interventi...
Approximately twenty million people in United States have some form of peripheral neuropathy. It has...
Abstract Background Targeting the endocannabinoid system has emerged as an effective strategy for th...
The CB2R agonist AM1710, examined in animal models of peripheral neuropathy, is effective in control...
A great need exists for the development of new medications to treat pain resulting from various dise...